Published in:
Open Access
01-07-2012 | Oral presentation
Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
Authors:
Fabrizio De Benedetti, Hermine Brunner, Nicola Ruperto, R Cuttica, Clara Malattia, Rayfel Schneider, Patricia Woo, Despina Eleftheriou, Eileen Baildam, Ruben Burgos-Vargas, Pavla Dolezalova, Stella M Garay, Rik Joos, Nico Wulffraat, Zbyszek Zuber, Francesco Zulian, Carine Wouters, Ricardo M Xavier, Lawrence Zemel, Stephen Wright, Andy Kenwright, Alberto Martini, Daniel Lovell
Published in:
Pediatric Rheumatology
|
Special Issue 1/2012
Login to get access
Excerpt
Treatment options for sJIA are limited. Excessive IL-6 production has been implicated in several manifestations of this disease. In a previous Japanese study, TCZ, an IL-6 receptor inhibitor, improved arthritis and systemic features of patients with refractory sJIA. We present efficacy and safety of TCZ in patients with active sJIA who were treated for ≥52 wks in the global, 3-part, 5-yr, phase 3, multicenter TENDER study. …
